MAP2K7 and lung carcinoma: Supporting its important oncogenic role independent of upstream EGFR signaling, MOS has been described in lung cancer models as essential activator of both MEK-ERK and phosphoinositide 3-kinase (PI3K)-AKT pathways in an EGFR-independent manner, compensating for the loss of EGFR activity [51].